175 results
S-8
EX-4.2
PRTG
Portage Biotech Inc
1 Dec 23
Registration of securities for employees
4:05pm
and outstanding shares immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding shares or other equity … transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
and a penetration enhancer. In animal models, the drug has shown efficacy in the majority of the animals, by a combination of direct killing of the cancer cells … combined with checkpoint inhibition. PORT-1 has shown proof of concept in humans in that the vast majority of the drug has been shown to stay in the tumor
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
in the majority of the animals, by a combination of direct killing of the cancer cells, and also a CD4 and CD8 T-cell response. Interim safety and survival … in humans in that the vast majority of the drug has been shown to stay in the tumor, and a dose equivalent to three times the approved dose
424B3
PRTG
Portage Biotech Inc
7 Nov 23
Prospectus supplement
4:50pm
corporate governance practices rather than those of Nasdaq. For example, British Virgin Islands law does not require that a majority of our board … , however, that where such a resolution is passed without the written consent of a majority of the shareholders (i.e., where for example one person
F-1
PRTG
Portage Biotech Inc
31 Oct 23
Registration statement (foreign)
4:05pm
. For example, British Virgin Islands law does not require that a majority of our board of directors consist of independent directors or that our board … the written consent of a majority of the shareholders (i.e., where for example one person holding 65% of the ordinary shares passes the resolution
6-K
EX-4.1
sl03tveng96 x9od6
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.3
02yv00a
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.2
y0r62q43xdn6v
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.4
brms1bzc ukseh
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-10.1
nwf 80e19uivea2
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.5
81eecpq6saoykm
3 Oct 23
Current report (foreign)
4:05pm
424B5
csrphvkuih5ichl2
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.2
m9rirkohpc9id3l2b
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
0og7qx
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
4ik3wyjsp7bt5wdh5h2l
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
EX-4.1
ziontu
22 Sep 22
Current report (foreign)
4:07pm
6-K
EX-99.2
aurux2t2dio0o2yufa
29 Aug 22
Current report (foreign)
4:00pm